$ATOS
ATOSSA THERAPEUTICS, INC.

2022 Q3 Form 10-Q Financial Statement

#000143774922019359 Filed on August 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.045M $3.162M $3.249M
YoY Change 3.14% -1.35% 51.12%
% of Gross Profit
Research & Development $5.160M $3.433M $1.499M
YoY Change 133.89% -9.63% 8.7%
% of Gross Profit
Depreciation & Amortization $2.000K $2.000K $2.000K
YoY Change -67.85% -60.4% -77.78%
% of Gross Profit
Operating Expenses $8.205M $6.595M $4.747M
YoY Change 59.05% -5.84% 34.44%
Operating Profit -$8.205M -$6.595M -$4.747M
YoY Change 59.05% -5.84% 34.44%
Interest Expense $0.00 -$85.00K -$29.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net $194.0K -$77.00K -$39.00K
YoY Change -603.23% 120.0% 457.14%
Pretax Income -$8.011M -$6.672M -$4.786M
YoY Change 54.14% -5.21% 35.27%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.011M -$6.672M -$4.785M
YoY Change 54.14% -5.21% 35.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06 -$0.05 -$0.04
Diluted Earnings Per Share -$63.27K -$52.69K -$37.79K
COMMON SHARES
Basic Shares Outstanding 126.6M 126.6M 126.6M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $117.4M $125.5M $131.5M
YoY Change -16.19% -11.86% -4.44%
Cash & Equivalents $117.4M $125.5M $131.5M
Short-Term Investments
Other Short-Term Assets $201.0K $1.570M $710.0K
YoY Change 1012.96% 1890.31% 819.22%
Inventory
Prepaid Expenses $5.107M $5.304M $3.874M
Receivables
Other Receivables
Total Short-Term Assets $123.4M $133.4M $136.8M
YoY Change -13.7% -8.51% -2.97%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.700M
YoY Change
Other Assets $629.0K $627.0K $630.0K
YoY Change 4591.23% 4576.31% 3725.6%
Total Long-Term Assets $3.329M $627.0K $630.0K
YoY Change 8955.3% 1590.62% 1179.63%
TOTAL ASSETS
Total Short-Term Assets $123.4M $133.4M $136.8M
Total Long-Term Assets $3.329M $627.0K $630.0K
Total Assets $126.7M $134.0M $137.5M
YoY Change -11.4% -8.1% -2.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.653M $2.052M $1.596M
YoY Change 147.46% 281.47% 120.97%
Accrued Expenses $117.0K $834.0K $120.0K
YoY Change 54.57% 56.88% -20.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.868M $3.792M $2.322M
YoY Change 71.14% 111.12% 68.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.868M $3.792M $2.322M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.868M $3.792M $2.322M
YoY Change 71.14% 111.12% 65.86%
SHAREHOLDERS EQUITY
Retained Earnings -$148.7M -$140.7M -$134.0M
YoY Change 19.53% 18.02% 23.38%
Common Stock $272.0M $270.4M $268.6M
YoY Change 2.59% 2.92% 6.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $123.9M $130.3M $135.2M
YoY Change
Total Liabilities & Shareholders Equity $126.7M $134.0M $137.5M
YoY Change -11.4% -8.1% -2.55%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$8.011M -$6.672M -$4.785M
YoY Change 54.14% -5.21% 35.25%
Depreciation, Depletion And Amortization $2.000K $2.000K $2.000K
YoY Change -67.85% -60.4% -77.78%
Cash From Operating Activities -$5.410M -$5.949M -$4.878M
YoY Change 76.71% 11.51% 10.66%
INVESTING ACTIVITIES
Capital Expenditures -$6.000K $0.00 $13.00K
YoY Change -36.17%
Acquisitions
YoY Change
Other Investing Activities -$2.700M
YoY Change
Cash From Investing Activities -$2.706M $0.00 -$13.00K
YoY Change 28687.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 $0.00
YoY Change -100.0% -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -5.410M -5.949M -$4.878M
Cash From Investing Activities -2.706M 0.000 -$13.00K
Cash From Financing Activities 0.000 0.000 $0.00
Net Change In Cash -8.116M -5.949M -$4.891M
YoY Change 239.3% -222.43% -104.99%
FREE CASH FLOW
Cash From Operating Activities -$5.410M -$5.949M -$4.878M
Capital Expenditures -$6.000K $0.00 $13.00K
Free Cash Flow -$5.404M -$5.949M -$4.891M
YoY Change 77.06% 11.51% 10.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1854000 usd
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126624000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126624000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126624000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126624000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
5493000 usd
atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2022Q2 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
0 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
0 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
-0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35610
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4753208
dei Entity Address Address Line1
EntityAddressAddressLine1
107 Spring Street
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98104
dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei City Area Code
CityAreaCode
206
dei Local Phone Number
LocalPhoneNumber
325-6086
dei Security12b Title
Security12bTitle
Common Stock, $0.18 par value
dei Trading Symbol
TradingSymbol
ATOS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
126624110
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
125537000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
136377000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5304000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2488000 usd
CY2022Q2 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
900000 usd
CY2021Q4 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
1072000 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1570000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1193000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
133421000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
141240000 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
627000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
141262000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5357000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
22000 usd
CY2022Q2 us-gaap Assets
Assets
134048000 usd
CY2021Q4 us-gaap Assets
Assets
141262000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2052000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1717000 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
834000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
204000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
875000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1184000 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
31000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
21000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3792000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3126000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
3792000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
3126000 usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
22792000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
22792000 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
247573000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
243996000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140691000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-129234000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
130256000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
138136000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134048000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3433000 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3799000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4937000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5177000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3162000 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3205000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6411000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
6595000 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
7004000 usd
us-gaap Operating Expenses
OperatingExpenses
11348000 usd
us-gaap Operating Expenses
OperatingExpenses
10534000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6595000 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7004000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11348000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10534000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-77000 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-109000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6672000 usd
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7039000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11457000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10577000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6672000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7039000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11457000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10577000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121572000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107160000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27168000 usd
CY2021Q1 atos Common Stock And Warrants Issued During Period Value New Issues
CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues
69668000 usd
CY2021Q1 atos Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
32760000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
640000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3538000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
139701000 usd
CY2021Q2 atos Common Stock And Warrants Issued During Period Value New Issues
CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues
10196000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1214000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7039000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
144072000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
138136000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1806000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4785000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
135157000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1771000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6672000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
130256000 usd
us-gaap Net Income Loss
NetIncomeLoss
-11457000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10577000 usd
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3577000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-1000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-0 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2816000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
578000 usd
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
-172000 usd
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
182000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
974000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-582000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
335000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1051000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142543000 usd
atos Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
0 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
630000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
438000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-309000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-263000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
10000 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
17000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10827000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9745000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-13000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
atos Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
0 usd
atos Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
69668000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
42956000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112624000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10840000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
102879000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
136487000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39664000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125647000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142543000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
125537000 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142433000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
125647000 usd
atos Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
13003000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>NOTE <em style="font: inherit;">1:</em> NATURE OF OPERATIONS</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"> Atossa Therapeutics, Inc. (the Company) was incorporated on <em style="font: inherit;"> April 30, 2009 </em>in the State of Delaware to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is currently focused on development of its pharmaceuticals for the treatment of breast cancer and other breast conditions, lung injury caused by cancer treatments, and the novel coronavirus (COVID-<em style="font: inherit;">19</em>). The Company’s fiscal year ends on <em style="font: inherit;"> December 31.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"><i>Impact of the Novel Coronavirus </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;">The ongoing COVID-<em style="font: inherit;">19</em> pandemic <em style="font: inherit;"> may </em>affect the Company's operations and those of <em style="font: inherit;">third</em> parties on which the Company relies, including causing possible disruptions in the supply of the Company's Endoxifen, AT-<em style="font: inherit;">H201,</em> AT-<em style="font: inherit;">301</em> and the pace of enrollment in our clinical trials.  In addition, the COVID-<em style="font: inherit;">19</em> pandemic <em style="font: inherit;"> may </em>affect the operations of the U.S. FDA and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals.  We do <em style="font: inherit;">not</em> yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole, however, we have <em style="font: inherit;">not</em> experienced a significant delay in the enrollment or the drug supply for our ongoing and planned clinical studies, including studies of Endoxifen, AT-<em style="font: inherit;">301</em> and AT-<em style="font: inherit;">H201.</em> If the number of COVID-<em style="font: inherit;">19</em> cases decline or if antiviral therapies (such as paxlovid) become widely adopted, it <em style="font: inherit;"> may </em>be difficult to enroll participants in our planned COVID-<em style="font: inherit;">19</em> clinical studies.</p>
us-gaap Net Income Loss
NetIncomeLoss
-11457000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10827000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
125537000 usd
CY2022Q2 atos Working Capital Deficit
WorkingCapitalDeficit
129629000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 54pt;"><i><b>Use of Estimates</b></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;text-indent:54pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 usd
CY2022Q2 atos Research And Development Current
ResearchAndDevelopmentCurrent
4488000 usd
CY2021Q4 atos Research And Development Current
ResearchAndDevelopmentCurrent
1853000 usd
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
579000 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
461000 usd
CY2022Q2 atos Professional Services Current
ProfessionalServicesCurrent
186000 usd
CY2021Q4 atos Professional Services Current
ProfessionalServicesCurrent
124000 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
51000 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
50000 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5304000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2488000 usd
CY2022Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
504000 usd
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
894000 usd
CY2022Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
244000 usd
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
183000 usd
CY2022Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
127000 usd
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
107000 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
875000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1184000 usd
CY2022Q2 atos Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
185000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 atos Consummate A Business Combination Percentage Of Acquired Outstanding Shares
ConsummateABusinessCombinationPercentageOfAcquiredOutstandingShares
0.50 pure
CY2022Q2 atos Consummate A Business Combination Percentage Of Aggregate Ordinary Voting Power
ConsummateABusinessCombinationPercentageOfAggregateOrdinaryVotingPower
0.50 pure
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21515000
CY2021Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10196000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
42956000 usd
CY2021Q2 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
5091000
atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
37154000
CY2021Q2 atos Stock Issued During Period Shares Warrant Exercised
StockIssuedDuringPeriodSharesWarrantExercised
5091000
atos Stock Issued During Period Shares Warrant Exercised
StockIssuedDuringPeriodSharesWarrantExercised
37154000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6672000 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7039000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11457000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10577000 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121572000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126624000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107160000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35511000
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35999000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34526000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34170000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3849000
CY2022Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
125332000 usd
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
136185000 usd
CY2022Q1 atos Lessee Operating Lease Monthly Rent Payments
LesseeOperatingLeaseMonthlyRentPayments
1000 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
2000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
8000 usd
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
7000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
12000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1771000 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1214000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3577000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1854000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10027000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.82
atos Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
50738000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
-0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
13876000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M21D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
183000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8418000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.72
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13876000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M21D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
183000 usd
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
5458000
CY2022Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.06 pure
CY2022Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
36000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
68000 usd
CY2021Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
13000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
46000 usd

Files In Submission

Name View Source Status
0001437749-22-019359-index-headers.html Edgar Link pending
0001437749-22-019359-index.html Edgar Link pending
0001437749-22-019359.txt Edgar Link pending
0001437749-22-019359-xbrl.zip Edgar Link pending
atos-20220630.xsd Edgar Link pending
atos20220630_10q.htm Edgar Link pending
ex_392260.htm Edgar Link pending
ex_392261.htm Edgar Link pending
ex_392262.htm Edgar Link pending
ex_392263.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
atos-20220630_lab.xml Edgar Link unprocessable
atos-20220630_def.xml Edgar Link unprocessable
atos-20220630_pre.xml Edgar Link unprocessable
atos20220630_10q_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atos-20220630_cal.xml Edgar Link unprocessable